ストックスクリーナーアプリを入手
2.65
9.50%
0.23
プレマーケット:
2.65
前日終値:
$2.42
開ける：
$2.46
24時間の取引高:
347.94K
Relative Volume:
1.48
時価総額：
$118.74M
収益：
$8,000
当期純損益:
$-32.15M
株価収益率:
-3.06
EPS:
-0.866
ネットキャッシュフロー:
$-26.37M
1週間 パフォーマンス:
+2.32%
1か月 パフォーマンス:
-10.77%
6か月 パフォーマンス:
-37.05%
1年 パフォーマンス:
-22.06%
1日の値動き範囲:
$2.455
$2.66
1週間の範囲:
$2.31
$2.66
52週間の値動き範囲:
$1.9875
$8.535
Genelux Corp Stock (GNLX) Company Profile
名前
Genelux Corp
セクター
電話
805-267-9889
住所
2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE
Compare GNLX vs VRTX, REGN, ALNY, ARGX, INSM
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GNLX
Genelux Corp
|
2.65 | 118.74M | 8,000 | -32.15M | -26.37M | -0.866 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Genelux Corp Stock (GNLX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-21 | 開始されました | Lake Street | Buy |
| 2024-10-29 | 開始されました | Guggenheim | Buy |
| 2024-08-28 | 開始されました | ROTH MKM | Buy |
| 2023-11-27 | 開始されました | H.C. Wainwright | Buy |
| 2023-09-12 | 開始されました | Maxim Group | Buy |
| 2023-02-15 | 開始されました | The Benchmark Company | Speculative Buy |
すべてを表示
Genelux Corp (GNLX) 最新ニュース
FY2029 Earnings Estimate for Genelux Issued By HC Wainwright - MarketBeat
Genelux (NASDAQ:GNLX) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Genelux (NASDAQ:GNLX) Price Target Cut to $20.00 by Analysts at Benchmark - MarketBeat
Genelux: Advancing Olvi-Vec Pivotal Program and Manufacturing Readiness Underpin Buy Rating and Long-Term Value Upside - TipRanks
Genelux Corp 2024 Annual Report: Oncolytic Virus Pipeline, Olvi-Vec Clinical Trials, Strategy, Risks, and Competitive Landscape 66686970719293 - Minichart
Gap Down: Can Genelux Corporation be recession proof2026 Fundamental Recap & Reliable Entry Point Trade Alerts - baoquankhu1.vn
Genelux (NASDAQ: GNLX) launches $100M at-the-market program with TD Cowen - Stock Titan
Genelux Establishes $100 Million At-The-Market Equity Program - TipRanks
Genelux Corp reports results for the quarter ended December 31Earnings Summary - TradingView
Genelux Establishes $100 Million ATM Equity Program With TD Cowen - TradingView
Genelux (NASDAQ: GNLX) launches $100M at-the-market stock plan - Stock Titan
Genelux Corporation Announces Phase 3 Trial Data Timeline and Interim Results for Olvi-Vec in Ovarian and Lung Cancer, Alongside Leadership Appointment - Quiver Quantitative
[10-K] GENELUX Corp Files Annual Report | GNLX SEC FilingForm 10-K - Stock Titan
GENELUX 2025 10-K: Revenue $0.01M, Net Loss $32.1M - TradingView
Cancer drug readout nears as Genelux says cash lasts into 2027 - Stock Titan
Aug Analyst Calls: What is the long term forecast for Genelux Corporation stockMarket Trend Review & Free Verified High Yield Trade Plans - baoquankhu1.vn
Genelux Corp. (GNLX) Gets a Buy from Maxim Group - The Globe and Mail
Genelux Corp expected to post a loss of 22 cents a shareEarnings Preview - TradingView
Insider Sell: John Thomas Sells 10,000 Shares of Genelux Corp (G - GuruFocus
Insider Selling: Genelux (NASDAQ:GNLX) Director Sells 10,000 Shares of Stock - MarketBeat
[Form 4] GENELUX Corp Insider Trading Activity - Stock Titan
[144] GENELUX Corp SEC Filing - Stock Titan
GNLX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
GNLX Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Can Genelux Corporation outperform in the next rallyJuly 2025 Selloffs & Smart Allocation Stock Reports - baoquankhu1.vn
Genelux Corporation to Participate in Upcoming Conferences - Yahoo Finance
Genelux executives to speak at two healthcare conferences - Stock Titan
8.2% Genelux (NASDAQ: GNLX) stake disclosed by holder Aladar Szalay - Stock Titan
Will Genelux Corporation stock continue dividend increasesMarket Activity Report & Safe Capital Growth Tips - mfd.ru
Genelux Updates Corporate Presentation for Investors and Stakeholders - The Globe and Mail
US Stocks Recap: Is Outlook Therapeutics Inc stock good for income investorsM&A Rumor & Safe Capital Growth Plans - baoquankhu1.vn
Genelux appoints Jason Litten as CMO - MSN
Brokers Offer Predictions for Genelux Q1 Earnings - Defense World
Aug Sectors: Will Genelux Corporation benefit from AI trendsExit Point & High Yield Stock Recommendations - baoquankhu1.vn
Aug Momentum: Will Genelux Corporation benefit from AI trendsRate Hike & Smart Money Movement Tracker - baoquankhu1.vn
Biotech Genelux to stream CEO and team in live Titan Partners fireside chat - Stock Titan
Genelux Announces Underwritten Public Offering to Raise Capital - The Globe and Mail
Can Genelux Corporation stock sustain revenue growth2025 Earnings Surprises & AI Powered Trade Plan Recommendations - Улправда
Genelux Corp Announces $20 Million Public Offering - TradingView — Track All Markets
Genelux Corporation announces pricing of $20.0 million underwritten public offering of common stock - MarketScreener
Genelux prices public offering of 6.67 million shares at $3 each - Investing.com Australia
Genelux prices public offering of 6.67 million shares at $3 each By Investing.com - Investing.com South Africa
Genelux Corporation Announces Pricing of $20 Million Public Offering of Common Stock | GNLX Stock News - Quiver Quantitative
Genelux Corporation Announces Pricing of $20.0 Million Underwritten Public Offering of Common Stock - Yahoo Finance
The Great Thaw: Biotech Fundraising Surges as Monte Rosa and Genelux Tap Reopening Markets - FinancialContent
Genelux stock falls after announcing proposed public offering By Investing.com - Investing.com Nigeria
Genelux stock falls after announcing proposed public offering - Investing.com
Genelux announces proposed public offering of common stock - Investing.com
Genelux Corporation Announces Proposed Public Offering of Common Stock - MarketScreener
Cancer-focused biotech Genelux plans new public stock sale to investors - Stock Titan
Genelux data update indicates disease early control, says H.C. Wainwright - MSN
Genelux Corp (GNLX) 財務データ
収益
当期純利益
現金流量
EPS
1.82%
大文字化:
|
ボリューム (24 時間):